as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences reported FY26 consolidated revenue of Rs. 3,129 cr (up 8%) and EBITDA of Rs. 1,120 cr (up 10%) with margin expansion to 36%. DBF segment grew 11% to Rs. 2,778 cr with EBITDA margin improving to 37%. Key misses included ~Rs. 105-110 cr revenue loss from delayed/abandoned launches (gSaxenda, Aspart, Esaxerenone) and insulin supply constraints from Bhopal plant delays. Strong performers were insulin (32% growth vs 6.7% CVM), derma (14.2% vs 8.6% CVM), and the newly launched generic Semaglutide brand SUNDAE which ranked #1 by volume and #2 by value in injectables. International Business grew 7% to Rs. 348 cr with 32% EBITDA margin. EU-GMP inspection found procedural observations; existing business minimally impacted but EU-CDMO pipeline delayed. Finance costs down 17% and net debt reduced to 2x EBITDA from 4x in FY24. PAT from operations grew 34% to Rs. 498 cr.
Eris delivered solid growth with margin expansion despite significant product launch setbacks. The SUNDAE Semaglutide launch is off to a strong start and in-sourcing of pen manufacturing from Q2 FY27 should improve margins. EU-GMP observations are procedural and manageable. FY27 guidance of 1.3x CVM growth for DBF and 18-20% for International Business signals confidence despite headwinds.